On May 26, 2023, Theseus Pharmaceuticals made headlines with a recent block trade of 1.1 million shares. The shares were sold at an average price of $7.50, which is below the current bid of $7.55. As a publicly traded company, Theseus Pharmaceuticals is identified by the stock symbol THRX. The company’s recent upgrade to a Zacks Rank #2 (Buy) is attributed to an upward trend in earnings estimates.
At the start of 2023, Theseus Pharmaceuticals’ stock was trading at $4.98. Since then, THRX stock has experienced a remarkable increase of 166.5%, and it is now trading at $13.27. As of May 20th, 2023, Theseus Pharmaceuticals is trading at $11.00, which marks a 1.85% increase since the beginning of the trading day.
THRX Stock Analysis: Fluctuating Prices and Negative Earnings Growth in the Health Technology Sector
On May 26, 2023, THRX stock opened at 7.30, which was lower than the previous day’s close of 8.64. Throughout the day, the stock’s price fluctuated between 7.30 and 8.56. The total volume of shares traded was 7,935, which was significantly lower than the average volume of 168,716 shares traded over the past three months. The market capitalization of THRX was $480.7 million.
THRX is a biotechnology company in the health technology sector. The earnings growth for this year is negative, with a decline of 19.63%. The price/book ratio is 2.06, which is relatively low, indicating that the stock may be undervalued.
THRX is expected to report its earnings on August 10, 2023. The EPS forecast for this quarter is -$0.38, which is a negative figure. Investors should keep an eye on THRX’s next earnings report to get a better idea of the company’s financial health.
Theseus Pharmaceuticals Inc (THRX) Stock Performance Soars After Bullish Report by Investment Analysts
On May 26, 2023, Theseus Pharmaceuticals Inc (THRX) experienced a significant increase in its stock performance, following the release of a bullish report by investment analysts. According to data from CNN Money, the 7 analysts offering 12-month price forecasts for the company have a median target of 23.00, with a high estimate of 24.00 and a low estimate of 18.00. This represents a +204.23% increase from the last price of 7.56. The current consensus among the 7 polled investment analysts is to buy stock in Theseus Pharmaceuticals Inc.
Discussion about this post